Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib dose-ranging study in inadequately controlled moderate to severe asthma
2022-502570-16-01Phase 2Authorised
- Sponsor
- Incyte
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of povorcitinib in asthma (4 arms), sponsored by Incyte. Primary endpoint: Absolute change from baseline in pre-bronchodilator FEV1 at Week 24. Planned start Jun 2024; status: authorised.
02
Drugs
povorcitinib
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-502570-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502570-16-01.